Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hypertension frequently coexists with diabetes mellitus, resulting in increased cardiovascular risk. Thus, BP control is crucial in decreasing morbidity and mortality in this difficult-to-treat patient population.
The objective of this study was to evaluate the efficacy and safety of aliskiren in hypertensive patients with diabetes not adequately responsive to the combination of valsartan and hydrochlorothiazide (HCT).
After a 1-to 4-week washout period, patients with a mean sitting diastolic BP (msDBP) ≥95 mmHg were treated with valsartan 160 mg for 2 weeks followed by valsartan/HCT 160 mg/25 mg for an additional 4 weeks (single-blind active run-in period). Patients whose msDBP remained ≥85 mmHg after the active run-in period were randomized (1 : 1) to receive aliskiren 150 mg (n = 184) or placebo (n = 179) as add-on therapy for 6 weeks. Aliskiren was then force-titrated to 300 mg once daily for another 6 weeks. Efficacy variables were: the change in msDBP and mean sitting systolic BP (msSBP) from baseline to week 12 endpoint, diastolic response (msDBP < 80 mmHg or reduction of at least 10 mmHg), and BP control rate (<130/80 mmHg).
Of the 363 patients randomized, 328 (90.4%) completed the study (aliskiren and placebo groups: 89.7% and 91.1%, respectively). At week 12 endpoint, the least squares mean (LSM) changes in msDBP (aliskiren vs placebo: −5.8 vs −4.8 mmHg; p = 0.2767) and msSBP (aliskiren vs placebo: −7.3 vs −4.8 mmHg; p = 0.0725) were numerically greater in patients treated with aliskiren compared with those treated with placebo; however, this difference was not statistically significant. The proportion of diastolic responders (aliskiren and placebo: 68.5% and 72.9%, respectively; p = 0.8482) and patients achieving BP control (aliskiren and placebo: 16.0% and 16.4%, respectively; p = 0.7511) were similar for both groups. Overall, 63 (34%) and 59 (33%) patients in the aliskiren and placebo groups, respectively, experienced adverse events (AEs). The most commonly reported AEs were headache (placebo group: 6.1%) and dizziness (aliskiren group: 4.4%). Aliskiren was well tolerated.
The reductions in BP with aliskiren added to valsartan/HCT in this study were numerically greater compared with placebo added to valsartan/HCT, although not statistically significant.
Trial Registration: http://clinicalTrials.gov identifier NCT00219102.
- Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053–9. CrossRef
- El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep 2004; 6: 215–23. CrossRef
- Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension 1995; 26: 869–79. CrossRef
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–246. CrossRef
- American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26: S80–2. CrossRef
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52. CrossRef
- Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes — an update. J Clin Hypertens (Greenwich) 2008; 10: 707–13; discussion 714–5. CrossRef
- Messerli FH, Grossman E, Goldbourt U. Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 2001; 14: 12S–6S. CrossRef
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62. CrossRef
- Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13. CrossRef
- Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment of cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886–92. CrossRef
- Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21 (4): 597–603. CrossRef
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861–9. CrossRef
- Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46. CrossRef
- Hayashi T, Takai S, Yamashita C. Impact of the renin-angiotensinaldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol 2010; 8 (2): 189–97. CrossRef
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60. CrossRef
- Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1: 221–8. CrossRef
- Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32 (10): 1873–9. CrossRef
- Tekturna. US prescribing information. Novartis Pharmaceuticals Corporation, East Hanover (NJ), 2010.
- Rasilez. EU summary of product characteristics. Novartis Europharm Ltd, Horsham, 2010.
- Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190–8. CrossRef
- Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139–85. CrossRef
- Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119(3): 371–3. CrossRef
- Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217–26. CrossRef
- Chrysant SG. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Expert Rev Cardiovasc Ther 2008; 6: 305–14. CrossRef
- Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, doubleblind trial. Lancet 2007; 370: 221–9. CrossRef
- Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047–55. CrossRef
- Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11–20. CrossRef
- Townsend RR, Forker A, Rumpelt P, et al. Initial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus [abstract no. LB-PO-03]. J Clin Hypertens 2010; 12 (7): 534.
- Zieve F, Yadao A, Yurkovic C, et al. Aliskiren with or without hydrochlorothiazide lowers blood pressure effectively in patients with stage 2 hypertension and metabolic syndrome [abstract no. PP.38.505]. J Hypertens 2010; 28 eSuppl. A:e600. CrossRef
- Whaley-Connell A, Sowers J, Purkayastha D, et al. Combination therapy with aliskiren and HCTZ decreases plasma renin activity and oxidative stress vs ramipril while reducing blood pressure in obese patients with stage 2 hypertension [abstract no. PO-66]. J Clin Hypertens 2010; 12 Suppl. 1: A46.
- Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839–45. CrossRef
- Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1423–31. CrossRef
- Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24 (5): 1663–71. CrossRef
- Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012–8. CrossRef
- Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination
American Journal of Cardiovascular Drugs
Volume 11, Issue 5 , pp 327-333
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. Renaissance Research and Hypertension of Texas, 5959 Harry Hines Boulevard, Suite 820, Dallas, TX, 75235-6209, USA
- 2. Institute of Cardiology, Kyiv, Ukraine
- 3. Department of Medicine, University of Seville, Seville, Spain
- 4. Novartis Pharma AG, Basel, Switzerland
- 5. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA